Latest Earnings Results: Q2 '26
Estimated EPS
$4.74
Reported EPS
$4.73
Surprise
-0.23%
Estimated Rev
$3.23B
Reported Rev
$3.33B
Surprise
+3.25%
$VRTX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $4.34 up 7.96% YoY • Reported revenue of $3.33B up 12.45% YoY • Vertex Pharmaceuticals raised its full year 2026 total revenue guidance to $13.1 billion to $13.2 billion, while reiterating guidance for combined GAAP and non-GAAP R&D, AIPR&D, and SG&A expenses.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $4.80 | -- | -- | N/A |
Q2 '26 | $4.74 | $4.73 | -0.23% | MISSED |
Q1 '26 | $4.24 | $4.47 | 5.35% | BEAT |
Q4 '25 | $5.11 | $5.03 | -1.58% | MISSED |
Q3 '25 | $4.58 | $4.80 | 4.91% | BEAT |